Skip to content

Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic

Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic : Prospective Multicenter Cohort Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05278390
Acronym
QUANTICO-PRO
Enrollment
500
Registered
2022-03-14
Start date
2022-06-13
Completion date
2025-06-30
Last updated
2022-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2 Infections, Respiratory Failure With Hypoxia

Brief summary

Automated quantification of the pulmonary volume impaired during acute respiratory failure could be helpful to assess patient severity during COVID-19 infection or perioperative medicine, for example. This study aims at assessing the correlation between the amount of radiologic pulmonary alteration and the clinical severity in two clinical situation : 1. SARS-CoV-2 infections 2. Postoperative hypoxemic acute respiratory failure.

Interventions

Automated quantitative analysis of altered pulmonary volume

Sponsors

REGION GRAND EST
CollaboratorUNKNOWN
E-MEDIA
CollaboratorUNKNOWN
VISIBLE PATIENT
CollaboratorUNKNOWN
University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject admitted to a care unit of the University Hospitals of Strasbourg or the University Hospital of Nancy and presenting a suspicion of SARS-CoV-2 infection or postoperative hypoxemic respiratory failure * Able to understand the objectives and risks of the research and to give dated and signed informed consent. Subjects may also be included in emergency or immediate life-threatening situations. * Subject with insurance covering

Exclusion criteria

* Pregnant woman (pregnancy confirmed by a urine or blood test) * Subject usually on home oxygen therapy * Subject under court protection * Subject under guardianship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
Correlation between altered pulmonary volume and ordinal severity scale2 days after CT scan (Day 2)This criterion will be expressed as a score between 1 (least severe) and 7 (most severe).

Secondary

MeasureTime frameDescription
Correlation between altered pulmonary volume and ordinal severity scale7 days after CT scan (Day 7)This criterion will be expressed as a score between 1 (least severe) and 7 (most severe).
Mortality90 days following CT scan (Day 90)
Rate of admission to intensive care unit28 days following CT scan (Day 28)
Initial length of hospitalization stay (in days)90 days following CT scan (Day 90)

Countries

France

Contacts

Primary ContactEric NOLL, MD PhD
eric.noll@chru-strasbourg.fr03 88 12 70 76

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026